Literature DB >> 19732746

Transcription variants of the prostate-specific PrLZ gene and their interaction with 14-3-3 proteins.

Ruoxiang Wang1, Hui He, Xiaojuan Sun, Jianchun Xu, Fray F Marshall, Haiyen Zhau, Leland W K Chung, Haian Fu, Dalin He.   

Abstract

We have reported isolation and characterization of the prostate-specific and androgen-regulated PrLZ gene abnormally expressed in prostate cancer. PrLZ is a potential biomarker for prostate cancer and a candidate oncogene promoting cell proliferation and survival in prostate cancer cells. A full delineation of the PrLZ gene and its gene products may provide clues to the mechanisms regulating its expression and function. In this report, we identified three additional exons in the PrLZ gene and recognized five transcript variants from alternative splicing that could be detected by RT-PCR and Western blotting. Structural comparison demonstrated that the PrLZ proteins are highly conserved among species. PrLZ contains multiple potential sites for interaction with other proteins. We used mammalian two-hybrid assays to demonstrate that PrLZ isoforms interact with 14-3-3 proteins, and multiple sites in the PrLZ may be involved in the interaction. Alternative splicing may contribute to abnormally enhanced PrLZ levels in prostate cancer, and interaction with 14-3-3 proteins may be a mechanism by which PrLZ promotes cell proliferation and survival during prostate cancer development and progression. This information is a valuable addition to the investigation of the oncogenic properties of the PrLZ gene.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19732746      PMCID: PMC3311924          DOI: 10.1016/j.bbrc.2009.08.165

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

Review 1.  14-3-3 proteins: active cofactors in cellular regulation by serine/threonine phosphorylation.

Authors:  Guri Tzivion; Joseph Avruch
Journal:  J Biol Chem       Date:  2001-11-14       Impact factor: 5.157

2.  Ratios of radical to conservative amino acid replacement are affected by mutational and compositional factors and may not be indicative of positive Darwinian selection.

Authors:  Tal Dagan; Yael Talmor; Dan Graur
Journal:  Mol Biol Evol       Date:  2002-07       Impact factor: 16.240

Review 3.  Genes differentially expressed in prostate cancer.

Authors:  I E Eder; J Bektic; P Haag; G Bartsch; H Klocker
Journal:  BJU Int       Date:  2004-05       Impact factor: 5.588

Review 4.  Scissors-grip model for DNA recognition by a family of leucine zipper proteins.

Authors:  C R Vinson; P B Sigler; S L McKnight
Journal:  Science       Date:  1989-11-17       Impact factor: 47.728

Review 5.  Phosphoserine/threonine-binding domains.

Authors:  M B Yaffe; A E Elia
Journal:  Curr Opin Cell Biol       Date:  2001-04       Impact factor: 8.382

6.  Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients.

Authors:  Gyorgy Petrovics; Wei Zhang; Mazen Makarem; Jesse P Street; Roger Connelly; Leon Sun; Isabell A Sesterhenn; Vasantha Srikantan; Judd W Moul; Shiv Srivastava
Journal:  Oncogene       Date:  2004-01-15       Impact factor: 9.867

7.  Alternative splicing as a mechanism for regulating 14-3-3 binding: interactions between hD53 (TPD52L1) and 14-3-3 proteins.

Authors:  Rose Boutros; Angela M Bailey; Sarah H D Wilson; Jennifer A Byrne
Journal:  J Mol Biol       Date:  2003-09-19       Impact factor: 5.469

Review 8.  Alternative splicing and biological heterogeneity in prostate cancer.

Authors:  Prabhakar Rajan; David J Elliott; Craig N Robson; Hing Y Leung
Journal:  Nat Rev Urol       Date:  2009-08       Impact factor: 14.432

9.  PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer.

Authors:  Ruoxiang Wang; Jianchun Xu; Outi Saramäki; Tapio Visakorpi; William M Sutherland; Jianguang Zhou; Buer Sen; So Dug Lim; Nicola Mabjeesh; Mahul Amin; Jin-Tang Dong; John A Petros; Peter S Nelson; Fray F Marshall; Haiyen E Zhau; Leland W K Chung
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

10.  Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization.

Authors:  T Visakorpi; A H Kallioniemi; A C Syvänen; E R Hyytinen; R Karhu; T Tammela; J J Isola; O P Kallioniemi
Journal:  Cancer Res       Date:  1995-01-15       Impact factor: 12.701

View more
  5 in total

1.  Tumor protein D54 is a negative regulator of extracellular matrix-dependent migration and attachment in oral squamous cell carcinoma-derived cell lines.

Authors:  Yoshiki Mukudai; Seiji Kondo; Atsushi Fujita; Yasuto Yoshihama; Tatsuo Shirota; Satoru Shintani
Journal:  Cell Oncol (Dordr)       Date:  2013-03-26       Impact factor: 6.730

2.  Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.

Authors:  Lei Li; Hongjun Xie; Liang Liang; Ye Gao; Dong Zhang; Leiya Fang; Soo Ok Lee; Jie Luo; Xingfa Chen; Xinyang Wang; Luke S Chang; Shuyuan Yeh; Yuzhuo Wang; Dalin He; Chawnshang Chang
Journal:  Carcinogenesis       Date:  2012-10-26       Impact factor: 4.944

3.  Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells.

Authors:  Tom Moritz; Simone Venz; Heike Junker; Sarah Kreuz; Reinhard Walther; Uwe Zimmermann
Journal:  Tumour Biol       Date:  2016-02-05

4.  PC-1/PrLZ confers resistance to rapamycin in prostate cancer cells through increased 4E-BP1 stability.

Authors:  Lan Yu; Zeng-Fu Shang; Jian Wang; Hongtao Wang; Fang Huang; Zhe Zhang; Ying Wang; Jianguang Zhou; Shanhu Li
Journal:  Oncotarget       Date:  2015-08-21

5.  DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk.

Authors:  Ana Cheong; Xiang Zhang; Yuk-Yin Cheung; Wan-Yee Tang; Jing Chen; Shu-Hua Ye; Mario Medvedovic; Yuet-Kin Leung; Gail S Prins; Shuk-Mei Ho
Journal:  Epigenetics       Date:  2016-07-14       Impact factor: 4.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.